BMS-话题@MedSci - 梅斯（MedSci）

#BMS#

60篇内容 | 2081人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1378651, encodeId=cf2f13e865197, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=Am J Transl Res：研究揭示Masquelet诱导膜促进BMSCs的成骨分化的机制, objectType=article, longId=138610, objectId=b29d138610d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b29d138610d3, replyNumber=0, likeNumber=51, createdTime=2018-05-21, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b29d138610d3, moduleTitle=Am J Transl Res：研究揭示Masquelet诱导膜促进BMSCs的成骨分化的机制, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b29d138610d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378650, encodeId=f56a13e865076, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=J Tissue Eng Regen Med：辛伐他汀通过增强BMSCs的自噬并抑制破骨细胞活性提高骨整合, objectType=article, longId=132536, objectId=38ae1325361c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=38ae1325361c, replyNumber=0, likeNumber=61, createdTime=2018-03-17, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=38ae1325361c, moduleTitle=J Tissue Eng Regen Med：辛伐他汀通过增强BMSCs的自噬并抑制破骨细胞活性提高骨整合, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=38ae1325361c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378649, encodeId=8a4413e8649fe, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=Cell Biol Int：BMSC-ExosMU通过增强骨形成和血管生成促进缺血性股骨头坏死的修复, objectType=article, longId=122883, objectId=8573122883a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8573122883a3, replyNumber=0, likeNumber=90, createdTime=2017-12-11, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8573122883a3, moduleTitle=Cell Biol Int：BMSC-ExosMU通过增强骨形成和血管生成促进缺血性股骨头坏死的修复, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8573122883a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378648, encodeId=176613e8648f2, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=Pharm Biol：SPC-I通过ERK1/2和p38-MAPK信号途径促进BMSC分化, objectType=article, longId=122099, objectId=9c2712209990, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c2712209990, replyNumber=0, likeNumber=62, createdTime=2017-12-04, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c2712209990, moduleTitle=Pharm Biol：SPC-I通过ERK1/2和p38-MAPK信号途径促进BMSC分化, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9c2712209990)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378647, encodeId=145113e8647e9, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=历史性一刻，BMS单抗Opdivo强势来袭，中国**款提交上市申请的PD-1/PD-L1类药物, objectType=article, longId=118721, objectId=3b83118e218f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b83118e218f, replyNumber=0, likeNumber=87, createdTime=2017-11-05, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b83118e218f, moduleTitle=历史性一刻，BMS单抗Opdivo强势来袭，中国**款提交上市申请的PD-1/PD-L1类药物, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3b83118e218f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378646, encodeId=e41313e864608, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=PD-1/PD-L1抗体“钱途”诱人，BMS、默沙东、罗氏、辉瑞四分天下, objectType=article, longId=93675, objectId=64f6936e500, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64f6936e500, replyNumber=0, likeNumber=59, createdTime=2017-03-29, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64f6936e500, moduleTitle=PD-1/PD-L1抗体“钱途”诱人，BMS、默沙东、罗氏、辉瑞四分天下, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=64f6936e500)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378645, encodeId=444613e8645df, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=市值935亿美元的BMS要卖？辉瑞罗氏诺华吉列德钱多到烧手……, objectType=article, longId=89245, objectId=f97c89245f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f97c89245f5, replyNumber=0, likeNumber=73, createdTime=2017-02-19, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f97c89245f5, moduleTitle=市值935亿美元的BMS要卖？辉瑞罗氏诺华吉列德钱多到烧手……, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f97c89245f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378644, encodeId=e77813e864480, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=瘤免疫又一喜讯！SMC批准BMS旗下PD-1药物Opdivo与Yervoy联合用于晚期皮肤癌一线治疗, objectType=article, longId=82087, objectId=8c028208e2d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c028208e2d, replyNumber=0, likeNumber=74, createdTime=2016-11-11, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c028208e2d, moduleTitle=瘤免疫又一喜讯！SMC批准BMS旗下PD-1药物Opdivo与Yervoy联合用于晚期皮肤癌一线治疗, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8c028208e2d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378643, encodeId=1f3013e864392, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=BMS与默沙东PD-1单抗一线治疗NSCLC临床数据大PK, objectType=article, longId=70083, objectId=e832e008317, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e832e008317, replyNumber=0, likeNumber=79, createdTime=2016-06-08, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e832e008317, moduleTitle=BMS与默沙东PD-1单抗一线治疗NSCLC临床数据大PK, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e832e008317)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378642, encodeId=19df13e8642e5, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=招募患者：PD-1抗体（BMS-936558）在中国晚期或复发性实体瘤受试者中的I、II期、开放性临床研究, objectType=article, longId=61205, objectId=623a61205d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=623a61205d3, replyNumber=0, likeNumber=62, createdTime=2015-12-29, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=623a61205d3, moduleTitle=招募患者：PD-1抗体（BMS-936558）在中国晚期或复发性实体瘤受试者中的I、II期、开放性临床研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=623a61205d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378641, encodeId=d32813e864146, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=BMS、默沙东及罗氏免疫治疗药物将成为ASCO会议的焦点, objectType=article, longId=35150, objectId=e77d351500c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e77d351500c, replyNumber=0, likeNumber=116, createdTime=2014-05-24, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e77d351500c, moduleTitle=BMS、默沙东及罗氏免疫治疗药物将成为ASCO会议的焦点, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e77d351500c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378640, encodeId=ace713e864029, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=BMS向美国提交阿扎那韦固定剂量HIV复方药物上市申请, objectType=article, longId=33504, objectId=1762335046a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1762335046a, replyNumber=0, likeNumber=62, createdTime=2014-04-18, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1762335046a, moduleTitle=BMS向美国提交阿扎那韦固定剂量HIV复方药物上市申请, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1762335046a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378639, encodeId=851113e86390c, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=百时美新HIV吸附抑制剂BMS-663068 IIb彰显疗效, objectType=article, longId=31687, objectId=517d3168e03, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=517d3168e03, replyNumber=0, likeNumber=68, createdTime=2014-03-12, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=517d3168e03, moduleTitle=百时美新HIV吸附抑制剂BMS-663068 IIb彰显疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=517d3168e03)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378638, encodeId=7d3313e863820, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=BMS拟将其糖尿病药物股份以30亿美元出让AZ, objectType=article, longId=28490, objectId=b01c2849011, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b01c2849011, replyNumber=0, likeNumber=68, createdTime=2013-12-25, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b01c2849011, moduleTitle=BMS拟将其糖尿病药物股份以30亿美元出让AZ, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b01c2849011)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378637, encodeId=cef813e863746, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=阿斯利康41亿美元打包收购BMS糖尿病产品, objectType=article, longId=28451, objectId=d5d2284519e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5d2284519e, replyNumber=0, likeNumber=47, createdTime=2013-12-25, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5d2284519e, moduleTitle=阿斯利康41亿美元打包收购BMS糖尿病产品, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d5d2284519e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378636, encodeId=460013e8636b4, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=BMS在日本提交丙型肝炎全口服治疗药物的上市申请, objectType=article, longId=26237, objectId=10812623e2b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=10812623e2b, replyNumber=0, likeNumber=63, createdTime=2013-11-07, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=10812623e2b, moduleTitle=BMS在日本提交丙型肝炎全口服治疗药物的上市申请, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=10812623e2b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378635, encodeId=3b4613e863566, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=百时美施贵宝抑郁药BMS-820836 II期试验失败, objectType=article, longId=23002, objectId=c9752300260, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c9752300260, replyNumber=0, likeNumber=95, createdTime=2013-08-17, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c9752300260, moduleTitle=百时美施贵宝抑郁药BMS-820836 II期试验失败, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c9752300260)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378634, encodeId=48ed13e8634a5, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=同单纯置入BMS相比DEB预扩后置入BMS无临床效果优势（DEB-AMI研究）, objectType=article, longId=5714, objectId=3da95e148e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3da95e148e, replyNumber=0, likeNumber=69, createdTime=2012-04-27, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3da95e148e, moduleTitle=同单纯置入BMS相比DEB预扩后置入BMS无临床效果优势（DEB-AMI研究）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3da95e148e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378633, encodeId=785c13e863351, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=ACC 2012：口服抗炎药减少BMS支架内晚期丢失, objectType=article, longId=4444, objectId=453d444478, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=453d444478, replyNumber=0, likeNumber=94, createdTime=2012-04-01, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=453d444478, moduleTitle=ACC 2012：口服抗炎药减少BMS支架内晚期丢失, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=453d444478)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378632, encodeId=f2de13e8632c6, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=DES较BMS改善CABG手术中静脉移植物损伤转归, objectType=article, longId=2526, objectId=aa8d252611, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa8d252611, replyNumber=0, likeNumber=111, createdTime=2011-04-11, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa8d252611, moduleTitle=DES较BMS改善CABG手术中静脉移植物损伤转归, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=aa8d252611)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

BMS

2020-05-29

canlab (审核中...)

前往app查看评论内容

#BMS#

Am J Transl Res：研究揭示Masquelet诱导膜促进BMSCs的成骨分化的机制

2018-05-21

canlab (审核中...)

前往app查看评论内容

#BMS#

J Tissue Eng Regen Med：辛伐他汀通过增强BMSCs的自噬并抑制破骨细胞活性提高骨整合

2018-03-17

canlab (审核中...)

前往app查看评论内容

#BMS#

Cell Biol Int：BMSC-ExosMU通过增强骨形成和血管生成促进缺血性股骨头坏死的修复

2017-12-11

canlab (审核中...)

前往app查看评论内容

#BMS#

Pharm Biol：SPC-I通过ERK1/2和p38-MAPK信号途径促进BMSC分化

2017-12-04

canlab (审核中...)

前往app查看评论内容

#BMS#

历史性一刻，BMS单抗Opdivo强势来袭，中国**款提交上市申请的PD-1/PD-L1类药物

2017-11-05

canlab (审核中...)

前往app查看评论内容

#BMS#

PD-1/PD-L1抗体“钱途”诱人，BMS、默沙东、罗氏、辉瑞四分天下

2017-03-29

canlab (审核中...)

前往app查看评论内容

#BMS#

市值935亿美元的BMS要卖？辉瑞罗氏诺华吉列德钱多到烧手……

2017-02-19

canlab (审核中...)

前往app查看评论内容

#BMS#

瘤免疫又一喜讯！SMC批准BMS旗下PD-1药物Opdivo与Yervoy联合用于晚期皮肤癌一线治疗

2016-11-11

canlab (审核中...)

前往app查看评论内容

#BMS#

BMS与默沙东PD-1单抗一线治疗NSCLC临床数据大PK

2016-06-08

canlab (审核中...)

前往app查看评论内容

#BMS#

招募患者：PD-1抗体（BMS-936558）在中国晚期或复发性实体瘤受试者中的I、II期、开放性临床研究

2015-12-29

canlab (审核中...)

前往app查看评论内容

#BMS#

BMS、默沙东及罗氏免疫治疗药物将成为ASCO会议的焦点

2014-05-24

canlab (审核中...)

前往app查看评论内容

#BMS#

BMS向美国提交阿扎那韦固定剂量HIV复方药物上市申请

2014-04-18

canlab (审核中...)

前往app查看评论内容

#BMS#

百时美新HIV吸附抑制剂BMS-663068 IIb彰显疗效

2014-03-12

canlab (审核中...)

前往app查看评论内容

#BMS#

BMS拟将其糖尿病药物股份以30亿美元出让AZ

2013-12-25

canlab (审核中...)

前往app查看评论内容

#BMS#

阿斯利康41亿美元打包收购BMS糖尿病产品

2013-12-25

canlab (审核中...)

前往app查看评论内容

#BMS#

BMS在日本提交丙型肝炎全口服治疗药物的上市申请

2013-11-07

canlab (审核中...)

前往app查看评论内容

#BMS#

百时美施贵宝抑郁药BMS-820836 II期试验失败

2013-08-17

canlab (审核中...)

前往app查看评论内容

#BMS#

同单纯置入BMS相比DEB预扩后置入BMS无临床效果优势（DEB-AMI研究）

2012-04-27

canlab (审核中...)

前往app查看评论内容

#BMS#

ACC 2012：口服抗炎药减少BMS支架内晚期丢失

2012-04-01

canlab (审核中...)

前往app查看评论内容

#BMS#

DES较BMS改善CABG手术中静脉移植物损伤转归

2011-04-11

科室
- - 订阅+
  - 更多科室
工具
服务